Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation

Published in: NewsWire
Date: 28 February 2018

Philogen S.p.A. Announces Authorization From FDA Of A Pivotal Registration Trial In U.S.A. For The Treatment Of Resectable Melanoma

Published in: BioSpace
Date: 12 October 2017

Philogen S.p.A. Announces Research Collaboration With Servier n The Field Of DNA-Encoded Chemistry

Published in: BioSpace
Date: 25 August 2017

Boehringer Ingelheim to Leverage Philogen’s DNA-Encoded Library Platform

Published in: Inside Precision Medicine
Date: 20 July 2017

Philogen S.p.A. Announces Exercise Of Options Within The License Agreement With Pfizer For The Development And Potential Commercialization Of Multiple Antibody Drug Conjugates (ADCs) And Targeted Technologies

Published in: CNN Money
Date: 21 January 2016

Philogen S.p.A. Announces Commencement Of Phase III Pivotal Trial In Melanoma

Published in: BioSpace
Date: 21 January 2016

Philogen S.p.A. Announces Collaboration With Johnson & Johnson Innovation

Published in: BioSpace
Date: 3 August 2016

Philogen S.p.A. Announces Expanded Research And Development Agreement With AbbVie

Published in: BioSpace
Date: 15 February 2016

Italy’s Philogen signs drug licence deal with Pfizer

Published in: Reuters
Date: 3 January 2013